Trial Profile
A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Nelarabine (Primary) ; Palifermin (Primary) ; Pegaspargase (Primary) ; Rituximab (Primary) ; Alemtuzumab; Cyclophosphamide; Cytarabine; Daunorubicin; Fludarabine; Imatinib; Melphalan; Mercaptopurine; Methotrexate; Vincristine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms UKALL-14
- 28 Nov 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 28 Nov 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.
- 01 Aug 2022 Status changed from active, no longer recruiting to completed.